TY - JOUR
TI - Angiogenic molecules in Hodgkin's disease: Results from sequential serum analysis
AU - Passam, F.H.
AU - Alexandrakis, M.G.
AU - Moschandrea, J.
AU - Sfiridaki, A.
AU - Roussou, P.A.
AU - Siafakas, N.M.
JO - International Journal of Immunopathology and Pharmacology
PY - 2006
VL - 19
TODO - 1
SP - 161-170
PB - Biolife s.a.s.
SN - 0394-6320
TODO - 10.1177/205873920601900116
TODO - angiogenin;  angiopoietin 2;  bleomycin;  cyclophosphamide;  doxorubicin;  etoposide;  interleukin 6;  prednisone;  procarbazine;  scatter factor;  tumor necrosis factor alpha;  vasculotropin;  vinblastine;  vincristine, adolescent;  adult;  aged;  angiogenesis;  article;  blood analysis;  cancer staging;  controlled study;  female;  Hodgkin disease;  human;  major clinical study;  male;  priority journal;  prognosis;  protein blood level;  sequential analysis
TODO - Increased angiogenic activity has been demonstrated in lymphoproliferative diseases including Hodgkin's disease. In the current study, the levels of circulating angiogenic molecules in 60 Hodgkin's patients were determined prior to and after treatment and correlated to disease stage and prognostic score. Hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were increased in Hodgkin's patients in comparison to healthy controls (p<0.001). Angiogenin and angiopoietin-2 levels did not differ from controls. HGF, VEGF, TNF-α and angiogenin decreased significantly in Hodgkin's patients after standard treatment (p<0.001 for HGF, p<0.05 for VEGF, TNF-α and angiogenin). Furthermore, HGF and TNF-α increased with advancing stage of disease (p<0.05). HGF and VEGF correlated significantly with IL-6 (r=0.56, p<0.0005 and r=0.57, p<0.001 respectively). In conclusion, Hodgkin's disease displays an angiogenic activity as depicted by the increased serum levels of a number of angiogenic cytokines. HGF seems to be the prominent molecule in Hodgkin's disease, which may be used to monitor the disease status and the response to treatment. Copyright © by Biolife, s.a.s.
ER -